Erratum in
-
Error in Figure Key.
[No authors listed]
[No authors listed]
JAMA Surg. 2024 Nov 1;159(11):1330. doi: 10.1001/jamasurg.2024.4216.
JAMA Surg. 2024.
PMID: 39259549
Free PMC article.
No abstract available.
No abstract available
Plain language summary
This study assesses nationwide trends in the use of observation for pancreatic neuroendocrine tumors 2 cm or smaller and to evaluate factors associated with resection.
PubMed Disclaimer
Conflict of interest statement
Conflict of Interest Disclosures: Dr Sukrithan reported personal fees from Exelixis and GE Health and funding to their institution from Eli Lilly and Company outside the submitted work. Dr Konda reported grants to their institution from Merck, Eisai, Xencor, and Eli Lilly and Company outside the submitted work. No other disclosures were reported.
References
-
-
Cloyd JM, Poultsides GA. The landmark series: pancreatic neuroendocrine tumors. Ann Surg Oncol. 2021;28(2):1039-1049. doi: 10.1245/s10434-020-09133-x
-
DOI
-
PubMed
-
-
Kos-Kudła B, Castaño JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343. doi: 10.1111/jne.13343
-
DOI
-
PubMed
-
-
Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1-33. doi: 10.1097/MPA.0000000000001454
-
DOI
-
PMC
-
PubMed
-
-
National Comprehensive Cancer Network . Neuroendocrine and adrenal tumors version 1. Accessed July 19, 2024. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
-
-
Partelli S, Massironi S, Zerbi A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109(12):1186-1190. doi: 10.1093/bjs/znac267
-
DOI
-
PMC
-
PubMed